EPASG – The ESCMID PK/PD of Anti-Infectives Study Group


The ESCMID PK/PD of Anti-Infectives Study Group (EPASG) was founded in 2010 by Ursula Theuretzbacher (Chairperson), Johan Mouton (Secretary), Françoise Van Bambeke (Treasurer), Alasdair MacGowan, Otto Cars, Nils Frimodt-Møller, Paul Tulkens.

The field of pharmacokinetics and pharmacodynamics (PK/PD) has recently seen increased interest and results as the importance of drug concentrations and dosing in preventing resistance becomes more and more evident. Supported by basic in vitro and in vivo studies as well as by clinical studies, PK/PD is now an integral part of anti-infective drug development. Within the PK/PD field, I have spoken and published regarding the need for revised dosage regimens for known drugs that have been available for decades and that offer resistance effective tools in the clinical setting. EPASG encourages and coordinates basic and translational research projects. The Study Group dissemination strategy intends to improve patient care via complimentary educational activities. Additionally, EPASG will establish a platform for sharing expertise among European countries, other ESCMID study groups, European committees, regulatory agencies, and other societies such as the International Society of Anti-Infective Pharmacology (ISAP).

In its founding year, the organizing committee focus has been on planning and preparing for activities. At the same time, EPASG has actively coordinated a variety of projects and several of these have already been successfully completed. The organizing committee is quite proud of its first 3 year results and looks forward to completion of ongoing projects. As some of these projects will take over a year, EPASG’s focus is turning towards gaining support which will be organised and pursued by designated EPASG project leaders.

You can find more detail on the activities of EPASG in our latest newsletter.